Key result
Autologous bone marrow cell implantation improves coronary perfusion in ~60% of patients without adverse effects.
Answers are grounded in this paper and cite their sources.
A new therapy for severe ischemic heart disease has been developed; therapeutic angiogenesis induced by the local implantation of autologous bone marrow cells (BMC). After confirming that no detrimental changes were induced by this treatment in a canine heart model, a clinical trial was commenced in 1999. Thus far, 5 patients have been given this new treatment concomitant with coronary artery bypass grafting and all have been followed up for at least 1 year. Autologous BMC were implanted into the ungraftable area and postoperative cardiac scintigraphy showed specific improvement in coronary perfusion in 3 of the 5 patients. Postoperative chest radiography, electrocardiography, echocardiography and blood tests did not reveal any detrimental changes. In conclusion, this new therapy appears to be safe and could provide a treatment option for patients with otherwise untreatable ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Hamano et al. (2001) studied Severe ischemic heart disease (n=5). Local implantation of autologous bone marrow cells (BMC) concomitant with coronary artery bypass grafting was evaluated on Specific improvement in coronary perfusion on postoperative cardiac scintigraphy. Local implantation of autologous bone marrow cells improved coronary perfusion in 3 of 5 patients (60%) without inducing detrimental changes.
Synapse has enriched 10 related papers. Consider them for comparative context: